Indivior Pharmaceuticals INDV Insider Ownership

NASDAQ INDV

$34.77 +0.90 (+2.66%)

At close: Oct 20, 2026 · 4:00 PM EDT

Insider Holdings by Owner

1.61Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

1.31%

▼-0.013% pp QoQ

Shares Held by Insiders

1.55Mn

filed for Sep 2026

▼-0.99% QoQ

Shares Outstanding

119.00Mn

119,000,000 shares

Direct Holdings

1.55Mn

Indirect: 0

Net Shares Traded (QoQ)

-15.59K

net selling in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 5, 2026

Over the trailing 12 months, INDV insiders bought $229,276 worth of shares (6.53K shares) and sold $2.83 million worth (73.17K shares) in open-market trades.

Counted by insider, open-market buying of INDV stock in the past 12 months came from 5 insiders and selling from 2 insiders.
Among INDV's insiders, Woodrow D. Anderson (Chief Accounting Officer) was the top open-market buyer in the past 12 months, with $107,955 of stock purchased (3K shares) and the latest purchase on August 27, 2026.
On the sell side, Christian Heidbreder (Chief Scientific Officer) led open-market sales of Indivior Pharmaceuticals stock over the past 12 months with $1.47 million (37.17K shares), most recently on July 10, 2026.
Outside the open market, Indivior Pharmaceuticals insiders received 242.76K shares in stock awards, acquired 1.57Mn shares through option exercises and conversions and gave up 796.9K shares to cover taxes or exercise prices over the past 12 months.
Business Quant data puts insider holdings in INDV at 1.55Mn shares across insiders' latest Form 4 filings, or 1.31% of the 119Mn shares outstanding; that total is down 0.99% from 1.57Mn shares at the end of Q2 2026.
Indivior Pharmaceuticals insiders report no indirect holdings: all 1.55Mn shares are held directly.
Business Quant counts 13 insiders with holdings in Indivior Pharmaceuticals stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
Indivior Pharmaceuticals' three biggest insider holders are Joseph Ciaffoni (Chief Executive Officer, 790.33K shares), Ryan Preblick (Chief Financial Officer, 284.75K shares) and Christian Heidbreder (Chief Scientific Officer, 209.34K shares), based on their latest Form 4 filings.
The largest insider, Joseph Ciaffoni, holds 50.88% of INDV's insider total.
In the last 12 months, 39 Form 4 filings with transactions in INDV stock came from 13 insiders.
The insider data for INDV reflects Form 4 filings through August 27, 2026.

Form 4 Holdings

Insiders Holding INDV

Insiders 13

Shares held 1.61Mn

Of outstanding 1.35%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Joseph Ciaffoni	Chief Executive Officer	790,330	790,330	49.1%	23 Jun, 2026
2	Ryan Preblick	Chief Financial Officer	284,751	284,751	17.7%	10 Jun, 2026
3	Christian Heidbreder	Chief Scientific Officer	209,337	209,337	13.0%	13 Jul, 2026
4	Jeffrey W Burris	Chief Legal Officer	71,518	71,518	4.4%	05 Mar, 2026
5	David E. Wheadon	Director	45,175	45,175	2.8%	14 May, 2026
6	Daniel A Ninivaggi	Director	44,086	44,086	2.7%	14 May, 2026
7	Mark Stejbach	Director	43,934	43,934	2.7%	14 May, 2026
8	Patrick A Barry	Chief Commercial Officer	31,380	31,380	1.9%	12 Feb, 2026
9	Woodrow D Anderson	Chief Accounting Officer	27,638	27,638	1.7%	27 Aug, 2026
10	Keith Humphreys	Director	21,844	21,844	1.4%	14 May, 2026
11	Barbara Ryan	Director	14,205	14,205	0.9%	14 May, 2026
12	Juliet Thompson	Director	12,973	12,973	0.8%	14 May, 2026
13	Stuart A Kingsley	Director	12,100	12,100	0.8%	14 May, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

59 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
27 Aug, 2026	Woodrow D Anderson	Chief Accounting Officer	Acquired P	1,500	$35.69	$53.54K	27,638	Direct
05 Aug, 2026	Woodrow D Anderson	Chief Accounting Officer	Acquired P	1,500	$36.28	$54.42K	26,138	Direct
10 Jul, 2026	Christian Heidbreder	Chief Scientific Officer	Disposed S	18,586	$41.14	$764.63K	209,337	Direct
22 Jun, 2026	Joseph Ciaffoni	Chief Executive Officer	Acquired M	1,266,903	—	—	1,402,879	Direct
22 Jun, 2026	Joseph Ciaffoni	Chief Executive Officer	Disposed F	612,549	$38.32	$23.47Mn	790,330	Direct
22 Jun, 2026	Joseph Ciaffoni	Chief Executive Officer	Disposed M	1,266,903	—	—	0	Direct
11 Jun, 2026	Christian Heidbreder	Chief Scientific Officer	Disposed S	18,586	$38.06	$707.38K	227,923	Direct
08 Jun, 2026	Ryan Preblick	Chief Financial Officer	Disposed S	36,000	$37.70	$1.36Mn	284,751	Direct
13 May, 2026	Stuart A Kingsley	Director	Acquired A	6,518	$0.00	$0	12,100	Direct
13 May, 2026	Keith Humphreys	Director	Acquired A	6,518	$0.00	$0	16,042	Direct
12 May, 2026	Juliet Thompson	Director	Disposed F	1,117	$38.28	$42.76K	6,455	Direct
13 May, 2026	Mark Stejbach	Director	Acquired A	6,518	$0.00	$0	27,087	Direct
13 May, 2026	Daniel A Ninivaggi	Director	Acquired A	6,518	$0.00	$0	27,163	Direct
13 May, 2026	Barbara Ryan	Director	Acquired A	6,518	$0.00	$0	12,242	Direct
13 May, 2026	David E. Wheadon	Director	Acquired A	10,430	$0.00	$0	30,780	Direct
13 May, 2026	Juliet Thompson	Director	Acquired A	6,518	$0.00	$0	12,973	Direct
14 Mar, 2026	Ryan Preblick	Chief Financial Officer	Acquired M	6,302	—	—	323,594	Direct
14 Mar, 2026	Ryan Preblick	Chief Financial Officer	Disposed F	2,843	$31.11	$88.45K	320,751	Direct
14 Mar, 2026	Ryan Preblick	Chief Financial Officer	Disposed M	6,302	—	—	0	Direct
13 Mar, 2026	Barbara Ryan	Director	Acquired P	8	$31.09	$249	5,724	Direct

Showing 1 to 20 of 59 transactions